uniQure N.V. (NASDAQ:QURE) Receives $37.82 Consensus Price Target from Analysts

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $37.82.

A number of analysts have commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of uniQure in a report on Thursday, May 29th. Cantor Fitzgerald upgraded shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. Wall Street Zen downgraded shares of uniQure from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Guggenheim reiterated a "buy" rating and issued a $28.00 price objective on shares of uniQure in a report on Monday, May 12th. Finally, Chardan Capital reiterated a "buy" rating and issued a $38.00 price objective on shares of uniQure in a report on Friday, May 30th.

uniQure Price Performance

Shares of QURE traded up $0.21 during mid-day trading on Thursday, hitting $14.49. 328,148 shares of the company were exchanged, compared to its average volume of 1,965,839. uniQure has a 1-year low of $3.76 and a 1-year high of $19.18. The company has a debt-to-equity ratio of 1.53, a quick ratio of 11.99 and a current ratio of 11.99. The company has a 50 day moving average of $14.54 and a 200-day moving average of $13.96. The stock has a market cap of $793.49 million, a price-to-earnings ratio of -3.30 and a beta of 0.08.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.25. The firm had revenue of $1.57 million during the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. Analysts expect that uniQure will post -3.75 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Jeannette Potts sold 4,670 shares of the business's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $15.14, for a total value of $70,703.80. Following the sale, the insider owned 115,073 shares in the company, valued at approximately $1,742,205.22. The trade was a 3.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Madhavan Balachandran sold 2,112 shares of the business's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the sale, the director owned 37,697 shares in the company, valued at $544,721.65. This represents a 5.31% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,144 shares of company stock worth $322,426. Corporate insiders own 4.79% of the company's stock.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently modified their holdings of the company. Vestal Point Capital LP raised its holdings in shares of uniQure by 58.4% in the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock valued at $50,801,000 after buying an additional 1,767,572 shares during the period. Nantahala Capital Management LLC raised its holdings in shares of uniQure by 3.8% in the 1st quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company's stock valued at $29,213,000 after buying an additional 101,598 shares during the period. Aberdeen Group plc raised its holdings in shares of uniQure by 46.8% in the 1st quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company's stock valued at $23,485,000 after buying an additional 706,216 shares during the period. Avoro Capital Advisors LLC purchased a new stake in shares of uniQure in the 4th quarter valued at $38,410,000. Finally, Franklin Resources Inc. raised its holdings in shares of uniQure by 33.1% in the 4th quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock valued at $35,103,000 after buying an additional 494,726 shares during the period. Hedge funds and other institutional investors own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.